These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease. Castro A; Martinez A Mini Rev Med Chem; 2001 Sep; 1(3):267-72. PubMed ID: 12369973 [TBL] [Abstract][Full Text] [Related]
4. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. Kaasinen V; Någren K; Järvenpää T; Roivainen A; Yu M; Oikonen V; Kurki T; Rinne JO J Clin Psychopharmacol; 2002 Dec; 22(6):615-20. PubMed ID: 12454562 [TBL] [Abstract][Full Text] [Related]
5. Lead optimization studies towards the discovery of novel carbamates as potent AChE inhibitors for the potential treatment of Alzheimer's disease. Roy KK; Tota S; Tripathi T; Chander S; Nath C; Saxena AK Bioorg Med Chem; 2012 Nov; 20(21):6313-20. PubMed ID: 23026084 [TBL] [Abstract][Full Text] [Related]
6. Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer's disease, on cholinesterase activity in rats. Kosasa T; Kuriya Y; Matsui K; Yamanishi Y Eur J Pharmacol; 2000 Feb; 389(2-3):173-9. PubMed ID: 10688981 [TBL] [Abstract][Full Text] [Related]
7. Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. Ogura H; Kosasa T; Kuriya Y; Yamanishi Y Methods Find Exp Clin Pharmacol; 2000 Oct; 22(8):609-13. PubMed ID: 11256231 [TBL] [Abstract][Full Text] [Related]
8. The new cholinesterase inhibitors for Alzheimer's disease, Part 2: illustrating their mechanisms of action. Stahl SM J Clin Psychiatry; 2000 Nov; 61(11):813-4. PubMed ID: 11105732 [No Abstract] [Full Text] [Related]
9. New insights into genetics and pathophysiology of Alzheimer's disease: what are the clinical and therapeutic implications? J Clin Psychiatry; 2000 Apr; 61(4):307-15. PubMed ID: 10830158 [No Abstract] [Full Text] [Related]
10. Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine. Suh DC; Arcona S; Thomas SK; Powers C; Rabinowicz AL; Shin H; Mirski D Drugs Aging; 2004; 21(6):395-403. PubMed ID: 15084141 [TBL] [Abstract][Full Text] [Related]
11. Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Jann MW Pharmacotherapy; 2000 Jan; 20(1):1-12. PubMed ID: 10641971 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit. Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443 [TBL] [Abstract][Full Text] [Related]
13. Cholinesterase inhibitors in Alzheimer's disease: donepezil or rivastigmine? Sharma JC Int J Clin Pract; 2002; 56(6):414-5. PubMed ID: 12166537 [No Abstract] [Full Text] [Related]
14. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Ballard CG Eur Neurol; 2002; 47(1):64-70. PubMed ID: 11803198 [TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Polinsky RJ Clin Ther; 1998; 20(4):634-47. PubMed ID: 9737824 [TBL] [Abstract][Full Text] [Related]
16. FDA approves new cholinesterase inhibitor for Alzheimer's disease. Am J Health Syst Pharm; 2000 Jun; 57(11):1026, 1028. PubMed ID: 10876742 [No Abstract] [Full Text] [Related]
17. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. Grossberg GT; Stahelin HB; Messina JC; Anand R; Veach J Int J Geriatr Psychiatry; 2000 Mar; 15(3):242-7. PubMed ID: 10713582 [TBL] [Abstract][Full Text] [Related]